HUE060822T2 - Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával - Google Patents

Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával

Info

Publication number
HUE060822T2
HUE060822T2 HUE18157578A HUE18157578A HUE060822T2 HU E060822 T2 HUE060822 T2 HU E060822T2 HU E18157578 A HUE18157578 A HU E18157578A HU E18157578 A HUE18157578 A HU E18157578A HU E060822 T2 HUE060822 T2 HU E060822T2
Authority
HU
Hungary
Prior art keywords
sost
agonist
administration
methods
bone growth
Prior art date
Application number
HUE18157578A
Other languages
English (en)
Hungarian (hu)
Inventor
Debra Ellies
Original Assignee
Ossifi Mab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39584303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE060822(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ossifi Mab Llc filed Critical Ossifi Mab Llc
Publication of HUE060822T2 publication Critical patent/HUE060822T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HUE18157578A 2006-12-29 2007-12-21 Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával HUE060822T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88264206P 2006-12-29 2006-12-29

Publications (1)

Publication Number Publication Date
HUE060822T2 true HUE060822T2 (hu) 2023-04-28

Family

ID=39584303

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18157578A HUE060822T2 (hu) 2006-12-29 2007-12-21 Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával

Country Status (12)

Country Link
US (8) US8178099B2 (OSRAM)
EP (3) EP4176884A1 (OSRAM)
JP (4) JP2010528002A (OSRAM)
DK (1) DK3345607T3 (OSRAM)
ES (2) ES2930183T3 (OSRAM)
FI (1) FI3345607T3 (OSRAM)
HU (1) HUE060822T2 (OSRAM)
LT (1) LT3345607T (OSRAM)
PL (1) PL3345607T3 (OSRAM)
PT (1) PT3345607T (OSRAM)
SI (1) SI3345607T1 (OSRAM)
WO (1) WO2009131553A2 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
EP1788986A1 (en) * 2004-08-30 2007-05-30 Spineovations, Inc. Method of treating spinal internal disk derangement
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
FI3345607T3 (fi) * 2006-12-29 2022-11-30 Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US8043620B2 (en) * 2007-11-21 2011-10-25 Amgen Inc. Wise binding agents and epitopes
US8469961B2 (en) * 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011239935A1 (en) * 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
AU2012236962B2 (en) 2011-03-25 2017-05-11 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
AU2012362898B2 (en) 2011-12-28 2017-11-09 Amgen, Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9770415B2 (en) * 2012-11-27 2017-09-26 Southwest Research Institute Delivery substrates from aligned polymer biomaterials for tissue repair
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
MX382085B (es) 2015-01-16 2025-03-13 Spineovations Inc Método de tratamiento de disco intervertebral
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN106202901A (zh) * 2016-07-04 2016-12-07 奥美之路(北京)健康科技股份有限公司 骨龄远程在线判读系统
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
US12338441B2 (en) 2018-02-12 2025-06-24 Aptacure Therapeutics Limited Aptamer for sclerostin and use thereof
CN119241705A (zh) 2018-03-30 2025-01-03 安姆根有限公司 C末端抗体变体
EP3920929A4 (en) * 2019-02-04 2023-02-22 Emory University SCLEROSTIN INHIBITORS THAT PROMOTE EXPRESSION OF BONE MORPHOGENETIC PROTEINS
CN114364694B (zh) * 2019-07-12 2024-05-10 国立大学法人京都大学 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN111658821A (zh) * 2020-06-03 2020-09-15 深圳市百吉因生物科技有限公司 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用
WO2024250012A2 (en) 2023-06-02 2024-12-05 33 Medical, Inc. Compositions for treatment of discogenic pain, and processes for making and using the same

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0054540A1 (en) 1980-04-07 1982-06-30 BERMAN Joel d/b/a JOEL BERMAN ASSOCIATES Window shade roller assembly
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE114473T1 (de) 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5344654A (en) 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
US5324819A (en) * 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5298852A (en) 1988-12-22 1994-03-29 Robert Bosch Gmbh Arrangement for and method of controlling a three-phase-generator in a vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5561173A (en) * 1990-06-19 1996-10-01 Carolyn M. Dry Self-repairing, reinforced matrix materials
WO1992015683A1 (en) 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU684041B2 (en) 1992-02-19 1997-12-04 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
CA2151486A1 (en) * 1993-01-12 1994-07-21 Arthur J. Ammann Tgf-beta formulation for inducing bone growth
TW303299B (OSRAM) 1993-07-22 1997-04-21 Lilly Co Eli
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
DE19647853A1 (de) * 1996-11-19 1998-05-20 Bioph Biotech Entw Pharm Gmbh Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität
US5939039A (en) 1997-01-16 1999-08-17 Orthovita, Inc. Methods for production of calcium phosphate
US6281195B1 (en) 1997-02-07 2001-08-28 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US20020098222A1 (en) * 1997-03-13 2002-07-25 John F. Wironen Bone paste
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
ATE250434T1 (de) * 1997-04-22 2003-10-15 Washington Res Found Knochentransplantate und -prothesen beschichtet mit tartratbeständiger säurephosphatase
US6025538A (en) 1998-11-20 2000-02-15 Musculoskeletal Transplant Foundation Compound bone structure fabricated from allograft tissue
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
JP2004521128A (ja) * 2001-02-23 2004-07-15 ワイス Ｂｍｐによるヒト骨髄由来ｃｄ１０５＋細胞の軟骨形成能
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
WO2002092000A2 (en) 2001-05-11 2002-11-21 Genome Therapeutics Corporation Hbm variants that modulate bone mass and lipid levels
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
DK2270052T3 (en) * 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
CN100515504C (zh) * 2001-10-12 2009-07-22 美国英佛曼公司 涂层,涂布体及其制造方法
WO2003039534A1 (en) 2001-11-08 2003-05-15 Merck & Co., Inc. Compositions and methods for treating osteoporosis
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
JP2005519067A (ja) * 2002-01-17 2005-06-30 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体を用いた骨成長および軟骨形成の刺激
JP3646167B2 (ja) 2002-02-19 2005-05-11 独立行政法人産業技術総合研究所 フォスフォフォリンを含む複合生体材料
WO2003073991A2 (en) 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
US7166133B2 (en) * 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20040002770A1 (en) 2002-06-28 2004-01-01 King Richard S. Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof
US20060246060A1 (en) * 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
KR20040023356A (ko) 2002-09-11 2004-03-18 현대모비스 주식회사 파킹브레이크 작동시 출발제한 시스템 및 그 방법
AU2002335562B2 (en) 2002-09-30 2007-07-05 Regen Biotech, Inc. Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers
JP3851602B2 (ja) * 2002-10-02 2006-11-29 ペンタックス株式会社 骨形成治療デバイス
WO2005028678A2 (en) 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
US6976816B2 (en) 2003-08-01 2005-12-20 Dana Corporation Combination lock washer and spindle bearing assembly
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005070439A1 (en) * 2004-01-09 2005-08-04 Regeneration Technologies Inc. Implant comprising a human muscle tissue matrix
US7189263B2 (en) 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
CA2567805A1 (en) * 2004-05-27 2005-12-15 Acceleron Pharma Inc. Tgf derepressors and uses related thereto
AU2005267722B2 (en) 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
JP2008517660A (ja) * 2004-10-22 2008-05-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 生物剤を送達する中空かつ多孔質の整形外科用または歯科用のインプラント
JP5328153B2 (ja) * 2005-01-06 2013-10-30 バクスター・インターナショナル・インコーポレーテッド 骨折修復のための強化（ｓｕｐｐｌｅｍｅｎｔｅｄ）マトリックス
US7531533B2 (en) * 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060198863A1 (en) 2005-03-03 2006-09-07 Musculoskeletal Transplant Foundation Ceramic composition for filling bone defects
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP2006320442A (ja) 2005-05-18 2006-11-30 Toshiba Ceramics Co Ltd リン酸カルシウム系骨補填材
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
WO2006135734A2 (en) 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
BRPI0617086B8 (pt) 2005-09-09 2021-06-22 Agnovos Healtcare Llc cimento composto substituto de enxerto ósseo e artigos dele originados
BRPI0618794A2 (pt) 2005-11-17 2011-09-13 Biomimetic Therapeutics Inc uso de uma matriz biocompatìvel, kit e composição para aumento ósseo, especialmente para aumento do osso maxilofacial
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
CN101378782A (zh) 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
EP2094731A2 (en) * 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
FI3345607T3 (fi) 2006-12-29 2022-11-30 Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
RS53157B (sr) 2007-03-20 2014-06-30 Eli Lilly And Company Antitela na sklerostin
CN101663043B (zh) 2007-04-27 2014-03-12 尤尼基因实验室公司 促进和保持骨生长的方法和组合物
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
RU2620071C2 (ru) * 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6511233B2 (ja) 2014-08-28 2019-05-15 株式会社竹中工務店 柱脚部と鉄骨梁との接合構造

Also Published As

Publication number Publication date
US20230226086A1 (en) 2023-07-20
PL3345607T3 (pl) 2023-01-09
JP2018199725A (ja) 2018-12-20
US11608373B2 (en) 2023-03-21
JP2010528002A (ja) 2010-08-19
US20150086571A1 (en) 2015-03-26
EP3345607B1 (en) 2022-10-26
EP2144613B1 (en) 2018-03-21
US20080160060A1 (en) 2008-07-03
JP2014074046A (ja) 2014-04-24
FI3345607T3 (fi) 2022-11-30
WO2009131553A3 (en) 2010-04-29
US8877196B2 (en) 2014-11-04
JP2017014263A (ja) 2017-01-19
US11891438B2 (en) 2024-02-06
US8178099B2 (en) 2012-05-15
WO2009131553A2 (en) 2009-10-29
EP4176884A1 (en) 2023-05-10
US20170044248A1 (en) 2017-02-16
US20120201815A1 (en) 2012-08-09
US20240360207A1 (en) 2024-10-31
EP3345607A1 (en) 2018-07-11
SI3345607T1 (sl) 2023-03-31
ES2666650T3 (es) 2018-05-07
LT3345607T (lt) 2023-01-10
US20230357377A1 (en) 2023-11-09
PT3345607T (pt) 2022-11-21
US20130195856A1 (en) 2013-08-01
US11807681B2 (en) 2023-11-07
ES2930183T3 (es) 2022-12-07
EP2144613A2 (en) 2010-01-20
DK3345607T3 (da) 2022-11-21

Similar Documents

Publication Publication Date Title
SI3345607T1 (sl) Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
HUS000509I2 (hu) Abemaciklib vagy egy gyógyászatilag elfogadható sója
IL196181A0 (en) Substituted n-phenylmethyl-5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
ZA200904446B (en) Methods of use for cyclopamine analogs
EP1996125A4 (en) GLENOID ELEMENT WITH ENHANCED FASTENING STABILITY
ZA201106538B (en) Compositions and methods for increasing muscle growth
IL194862A0 (en) Maleate co-crystal of azd1152
IL196706A0 (en) Crystalline forms of rapamycin analogs
AP2008004406A0 (en) Methods of managing timberland
ZA200808245B (en) Compositions and methods for inducing bone growth and inhibiting bone loss
GB0705854D0 (en) Methods of construction
IL206479A0 (en) Crystalline forms of palonosetron hydrochloride
AP2784A (en) Methods of managing timberland
ZA200806508B (en) Salt of CD80 Antagonist
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
IL197192A0 (en) Preparation of decahalodiphenyl ethane
ZA200810726B (en) Substituted N-Phenylmethyl -5-OXO-Proline-2-Amides AS P2X7-Receptor Antagonists and their methods of use
ZA201108374B (en) Methods of administration of thrombopoietin agonist compounds
ZA200900740B (en) Crystalline forms of rapamycin analogs
EG24395A (en) New method for depittering of apricot seed
ZA200900669B (en) Spinal prosthesis with offset anchors
GB0601140D0 (en) Tissue monitor
AU2007902502A0 (en) Game fishing chair
GB0604819D0 (en) Methods of analysing cell growth behaviour
HK1175109A (en) Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof